S&CO Inc. takes position in AstraZeneca as EPS tops estimates
S&CO Inc. bought 37,990 AstraZeneca shares worth about $7.10M, joining other funds that increased stakes during the quarter. Investors Research added a new position valued at $122K, while Spinnaker Investment Group grew its holding. Analyst ratings skew Buy, and AstraZeneca reported Q2 EPS of $2.63, beating the $2.50 consensus.